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ABSTRACT 
Xia sheng: Chronic arsenic exposure perturbs  
gut microbiota and bile acid homeostasis 
(Under the direction of  Kun Lu) 
Chronic arsenic exposure perturbs mammalian metabolome. Gut microbiota regulates the 
host metabolic homeostasis, and previous studies have demonstrated that arsenic exposure can 
cause gut microbiota dysbiosis. However, it still unclear whether arsenic-induced gut microbiota 
dysbiosis plays a role in the arsenic-perturbed metabolic imbalance in the host body. Bile acids 
are the functional compounds synthesized in host bodies but regulated by gut microbiota. In this 
study, we exposed C57BL/6 mice to1 ppm arsenic in drinking water for 3 months and 
investigated whether arsenic exposure affects the bile acid homeostasis in mouse sera and livers 
and whether it is related to the changes in gut bacteria. We found that arsenic exposure caused 
the decline of major unconjugated primary bile acids in sera. The ratios of unconjugated bile 
acids and taurine-conjugated bile acids were also decreased. However, the hepatic level of 
several primary bile acids, including TMCA, MCA, TCA, was significantly increased in 
arsenic-treated mice. Secondary bile acids were consistently decreased both in sera and livers by 
arsenic treatment. Moreover, the relative abundance of Bacteroidetes and Firmicutes was 
differentially changed by arsenic exposure, which was associated with the bile acid level in sera. 
  iv 
In summary, this study demonstrates that arsenic exposure perturbs the bile acid homeostasis and 
arsenic-induced gut microbiota dysbiosis could play a role in this process, which suggests the 
important role of gut microbiota in arsenic-associated toxicity.  
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Arsenic, a well-known poison, is now widely acknowledged as one of the world's most 
serious environmental threats, posing a danger to the lives of hundreds of millions of individuals. 
Arsenic exists in nature mainly in the form of sulfide minerals (e.g., As4S4, As2S3, etc.). 
Arsenic and its compounds are mainly used in alloy smelting, pesticides and pharmaceuticals, 
pigments and other industries, but also often exist as impurities in raw materials, waste residues, 
semi-finished products and finished products. Arsenic contamination in water or food is a global 
issue affecting hundreds of millions of people (1). In the above production or use of arsenic 
compounds, such as improper protection inhalation of arsenic-containing air or ingestion of 
arsenic-contaminated food and drink, there is often the possibility of acute and chronic arsenic 
poisoning. Arsenic compounds can be absorbed through the respiratory tract, skin and digestive 
tract (2). They are distributed in the liver, kidneys, lungs, gastrointestinal wall, and spleen 
(2).They are mainly excreted through urine and feces (2). They can pass through the placental 
barrier and damage the fetus (2).  
Elemental arsenic is basically non-toxic. However, its oxides and arsenates are more toxic, 
and trivalent arsenic is more toxic than pentavalent arsenic (3).  
Arsenic can bind to enzymes containing sulfhydryl groups in cells and inhibit the cellular 
oxidation process; it can also paralyze the vasomotor center and make capillaries paralyzed, 
dilated and permeability increased. Acute arsenical poisoning is mostly seen when arsenicals 
contaminate food or drinking water, accidental ingestion or suicide (4). Clinical manifestations 
are more common in the "acute gastroenteritis type". In severe cases, shock, liver damage, and 
even death from toxic myocardial damage can occur. Arsenic smelting and arsenic trioxide 
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production workers, as well as long-term arsenic pollution of the atmosphere and drinking water, 
or long-term consumption of arsenic agents, chronic arsenic poisoning can occur. Prominent 
manifestations are skin hyperpigmentation, hyperkeratosis or warty hyperplasia, also seen as 
leukopenia or anemia. It has been recognized that long-term exposure to arsenic compounds can 
cause skin cancer and lung cancer (2). 
Currently, many developing countries are still using water resources with excessive arsenic 
content, and the local population is continuously exposed to arsenic. Therefore, it is important to 
study the pathogenesis of arsenic and its impact on human health. However, arsenic pathogenesis 
is very complex that although it has been studied for centuries, the whole picture of arsenic toxic 
effects is still unclear and the underlying mechanisms aren’t fully understood. Numerous studies 
reveal that arsenic exposure perturbs metabolic homeostasis in animals or humans. For example, 
arsenic exposure disturbs the lipid and cholesterol homeostasis in animals and humans, which is 
associated with arsenic-induced cardiovascular diseases (5, 6). Recent studies have revealed that 
gut microbiota has complex interactions with arsenic. The gut microbiome, as defined by 
molecular biologist Joshua Lederberg, is the totality of microorganisms, bacteria, viruses, 
protozoa, and fungi, and their collective genetic material present in the gastrointestinal tract 
(GIT). The gut microbiota is comprised of all the bacteria, commensal, and pathogenic, residing 
in the GIT. In the past decade the gut microbiota has been explored for potential gut microbe–
host interactions including effects on metabolism, immune, and neuroendocrine responses (7). 
The gut microbiota plays an important role in nutrient and mineral absorption, synthesis of 
enzymes, vitamins and amino acids, and production of short-chain fatty acids (SCFAs). The 
fermentation byproducts acetate, propionate, and butyrate are important for gut health and 
provide energy for epithelial cells, enhance epithelial barrier integrity, and provide 
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immunomodulation and protection against pathogens. Current investigations are exploring 
resident bacterial gene function and the potential corresponding role in human health and 
metabolism. Additionally, study of whether nonpathogenic bacterial strains can stimulate 
recovery of the immune responses to pathogenic causing diseases is ongoing (8). 
On the one hand, gut microbiota status can profoundly affect arsenic metabolism and its 
toxic effects on host bodies (5, 9). Conventional mice and antibiotic-treated mice which have a 
disrupted gut microbiota have a distinct cholesterol and lipid profiles in the context of arsenic 
exposure (5). On the other hand, arsenic exposure can significantly perturb the normal gut 
microbiota, including changing the community composition, functional genes and metabolites 
(10). Since the critical role of gut microbiota in host health, causing gut microbiota dysbiosis 
could be one of the important aspects of arsenic toxicity. However, whether arsenic-perturbed 
gut microbiota can influence host bodies is still unclear.  
By applying liquid chromatography-mass spectrometry (LC/MS)-based untargeted 
metabolomics, our and others’ previous studies have demonstrated that arsenic exposure 
significantly changes the metabolite repertoire of sera, feces, and urine in animal models and 
humans (11-14). Our recent study suggested that changes in the fecal metabolome of arsenic-
treated mice could result from arsenic-perturbed gut microbiota (10, 15). However, it is still 
unclear whether arsenic-induced gut microbiota changes can influence the metabolic repertoire 
in host bodies.  
Bile acids are hydroxylated steroids, synthesized in the liver from cholesterol. Bile acids are 
normally conjugated in the liver to the amino acids, Gly and Tau, or sulfate. After synthesis by 
hepatocytes, primary bile acids will be transported and stored in the gall bladder, and will be 
secreted into the lumen of the intestine after meals to absorb dietary lipids and cholesterol, and 
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will be recycled by distal ileum to back to our bodies. This process is known as the enterohepatic 
circulation. The active transport of bile acids across canalicular membranes of hepatocytes is a 
primary driving force for bile flow. Duodenal emulsification of fat requires bile acids micelles 
and biliary lecithin. The distal ileum actively reabsorbs bile acids, against their concentration 
gradient. As bile acids return to the liver through the EHC, they inhibit cholesterol biosynthesis, 
as well as further bile acids biosynthesis. Secondary bile acids, deoxycholate and lithocholate, 
are formed through bacterial 7α-dehydroxylation of the primary bile acids, cholate and 
chenodeoxycholate, respectively (16). Glucose, insulin and glucagon also appear to help regulate 
bile acids biosynthesis (16). Bile acids are ligands for many nuclear receptors, such as the 
farnesoid X receptor (FXR), as well as a G protein-coupled receptor (TGR5) (17).  Bile acids 
appear to inhibit hepatic PEP carboxykinase activity, while stimulating glycogen synthase 
activity. Bile acids therapies may be used in the treatment of various forms of liver disease, 
diabetes mellitus and obesity. 
Bile acids are tightly regulated by gut bacteria. Gut bacteria can metabolize the secreted 
primary bile acids, which not only diversifies the bile acid profiles but also largely determine the 
activation level of bile acid downstream signaling pathways (17, 18). Accumulating evidence 
indicates that gut microbiota-performed bile acid metabolism plays an important role in 
regulating bile acid synthesis and controlling the bile acid pool, as well as some other metabolic 
pathways in the host (17). Gut microbiota dysbiosis has been associated with altered bile acid 
metabolism (19, 20). However, whether arsenic-induced gut microbiota dysbiosis perturbs bile 
acid metabolism is still unknown. 
In this study, we will explore whether chronic arsenic exposure changes bile acid 
homeostasis and whether arsenic-induced gut microbiota dysbiosis plays a role in this process. 
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Previous studies utilize LC/MS-based untargeted metabolomics to illustrate the alterations in 
overall metabolic profiles which provide important clues to understand the toxic effects by 
arsenic exposure and its pathogenic mechanisms (11-15). However, many bile acid species 
cannot be well extracted, measured or quantified by untargeted methods. Therefore, in this study, 
we investigate the effects of chronic arsenic exposure on bile acid homeostasis with a LC/MS-
based targeted method.  
 
Methods 
Animals, arsenic exposure and fecal transplantation. 7-8-week C57BL/6 male mice 
(specific pathogen-free grade) were purchased from Jackson Laboratories (Bar Harbor, ME). 
Mice were maintained at the University of North Carolina animal facility in static microisolator 
cages with Bed-O-Cob (The Andersons Inc., Maumee, OH) combination bedding under standard 
environmental conditions (22°C, 40–70% humidity, and a 12:12-h light: dark cycle). Mice were 
monitored for 1 week at the animal facility without any treatment. Pelleted rodent diet and 
sterilized tap water were provided to the mice ad libitum. Sodium arsenite was obtained from 
Fisher Scientific and exposed to mice by drinking water. Three groups of mice were set: Control 
group (n=15), and arsenic-dosing group (1 ppm; n=15). After 3-month exposure, fecal samples 
were collected for microbiota analysis. Then, mice were euthanatized, and heart blood and liver 
samples were collected as previously described (5). All samples were then stored at −80 C until 
use. The experimental protocol was approved by the University of North Carolina Animal Care 
Committee and mice were treated humanely. 
16S rRNA gene sequencing and data analysis. 16S rRNA gene sequencing was performed as 
described previously (21). Fecal DNA was isolated using a PowerSoil® DNA Isolation Kit 
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following the instructions of the manufacturer (Qiagen, Hilden, Germany). Then,  PCR was 
performed to amplify the bacterial 16S rRNA gene (V4 regions) using universal primers (iTRU-
A 515 F and iTRU-1 806 R, Table S1), as previously described (10). The library was sequenced 
by Illumina MiSeq and pair-ended 250 × 250 reads were generated. Raw data were first set-
paired, trimmed, and merged in Genenious (version 10.0.3, Biomatters Ltd., New Zealand) and 
the taxonomy of gut microbiota of each sample was analyzed using quantitative insights into 
microbial ecology (QIIME) (22). UCLUST was used to choose operational taxonomic units 
(OTUs) with a threshold of 97% sequence similarity and the ribosomal database project (RDP) 
classifier was used to select the representative set of sequences. 
Bile acid measurement. The sample preparation procedure was based on the method previously 
published with slight modifications (23, 24). Briefly, for serum samples, 20 µL of 1 µM internal 
standard mixture of bile acids and 160 µL ice-cold methanol were added to 20 μL of sera. Bile 
acids are dissolved in methanol. Samples were mixed by vortexing for 30 s and then incubated at 
−20 °C for 30 min(Samples didn’t freeze) and centrifuged at 15,000 × rpm for 10 min. The 
supernatant was dried down in a SpeedVac and reconstituted in 100 µL of methanol: H2O (75: 
25, v/v) for liquid chromatography-mass spectrometry analysis. For liver samples, around 25 mg 
of livers were weighed and extracted with 600 µL of acetonitrile and methanol in order. 20 µL of 
1 µM internal standard mixture of bile acids was added before the extraction. For each extraction, 
tissue samples were homogenized on TissueLyzer at 50Hz for 15 minutes followed by 
centrifuging at 16, 000 rpm for 10 min. The extracts were dried in a SpeedVac (Thermo Fisher 
Scientific, Waltham, MA). The analytes were reconstituted in 200 µL and diluted to 1.2 mL with 
water (0.2% FA). The mixture was passed through an ISOLUTE C18 cartridge (100 mg/1 mL), 
which was washed with 2 mL of methanol and conditioned with 2 mL of methanol: water (0.1% 
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FA) = (1:5) before analysis. Followed the sample loading, the cartridge was washed with 2 mL 
of methanol: water (0.1% FA) = (1:5). Bile acids were eluted with 600 × 2 µL of methanol. The 
eluates were dried in a SpeedVac and reconstituted in 200 µL of methanol: H2O (75: 25, v/v) for 
liquid chromatography-mass spectrometry analysis.  
The extracted bile acids were analyzed in a TSQ Quantis triple quadrupole mass 
spectrometer (Thermo Scientific, Waltham, MA, USA) with an electrospray ionization (ESI) 
source operated in negative ion mode. The chromatography separation was carried out in an 
Agilent 1290 Infinity II UPLC system (Agilent Technologies, Santa Clara, CA) and an 
ACQUITY UPLC HSS T3 (2.1 mm × 100 mm, 1.8 µm) column (Waters Inc., Milford, MA, 
USA). 0.01% formic acid in water was used as mobile phase A and 0.01% formic acid in 
acetonitrile was used as mobile phase B. The injection volume was 10 µL, the column was 
maintained at 60 °C, and the flow rate was 400 µL/min. The gradient elution of mobile phase 
started at 25% B, held for 2 min; then increased to 40% B in 13 min; then increased to 98% B at 
20 min, held for 2 min; then decreased to 25% B at 22.5 min, and held for 3.5 min, for a total run 
of 26 min. The source parameters were set as follows: spray voltage, 3500 V; sheath gas, 50 
arbitrary unit; aux gas, 25 arbitrary unit; sweep gas, 6 arbitrary unit; ion transfer tube 
temperature, 325 °C; vaporizer temperature, 350 °C. MRM transitions used for each bile acid 
were shown in Table S2. The quantification of bile acids was based on the isotope dilution 
method with the responses of d4-TβMCA (for TαMCA, TβMCA, TωMCA), d4-CA (for TCA, 
αMCA, βMCA, and CA), d9-TCDCA (for TCDCA), d9-CDCA (for CDCA), d6-DCA (for 
DCA), and d4-LCA (for LCA). At least eight-point calibration curves with concentrations 
ranging from 0.1-1000 nM are employed. The regression coefficients were ≥  0.99 for all 
calibration curves. LODs for bile acids are all below 0.5 nM. 
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Statistical analysis. The difference of bile acid concentration between control and treated mice 
was analyzed by Dunnett’s multiple comparisons test in unpaired t test in Prism 8 software 
(GraphPad). The statistical differences of gut microbiota components of two mouse groups were 
calculated by the Metastats command within the MOTHUR software. The correlation coefficient 
and associated p-values were calculated by Pearson Correlation in Prism 8 software (GraphPad). 
A p-value of less than 0.05 was considered a significant difference. 
 
Results 
1. Arsenic exposure perturbed bile acid homeostasis in mouse sera. 
We first investigated the effects of arsenic exposure on systemic bile acids. After 3-month 
arsenic exposure, we measured the bile acid profiles in mouse sera. As shown in Figure 1A-C, 
we found arsenic exposure significantly decreased the level of three major unconjugated primary 
bile acid species, including MCA, CA and CDCA. However, taurine-conjugated bile acids were 
moderately increased by arsenic-treated group but didn’t have a significant difference between 
control mice and arsenic-treated mice. Moreover, two dominant secondary bile acids, including 
DCA and LCA, were significantly decreased in arsenic-treated mice (Figure 1D). Both DCA and 
LCA are the major secondary bile acid species synthesized by gut bacteria (18). Another 
important role of gut microbiota in bile acid metabolism is to cleave the taurine group from 
conjugated bile acid. We then calculated the ratio of unconjugated bile acids and their 
corresponding taurine-conjugated forms. As shown in Figure 2, we found arsenic-treated mice 
have a significantly lower ratio than control mice. Taken together, these results suggest that 1 
ppm arsenic exposure affects the bile acid homeostasis in mouse sera. 
  ９
 
Figure 1. Arsenic exposure perturbed serum bile acid homeostasis. (A-C). Arsenic exposure decreased 
the level of unconjugated primary bile acids but didn’t affect the level of their taurine-conjugated forms. 
(D). Arsenic exposure significantly reduced the level of secondary bile acids in mouse sera. (Unpaired t 
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Figure 2. Arsenic exposure reduced the ratios of unconjugated bile acids and conjugated bile acids in the 
mouse sera. (Unpaired t test, N.S.: no significant difference; *p<0.05; **p<0.01; n=6-8; Error bars show 
the SEM) 
 
2. Primary bile acids were increased in the livers of arsenic-treated mice. 
Bile acids are originally synthesized from cholesterol in livers. We next investigated the 
effects of arsenic exposure on hepatic bile acids. As shown in Figure 3A-C, the level of TMCA, 
MCA, TCA was significantly increased in arsenic-treated mouse livers compared with control 
mice. Similar to sera, we found secondary bile acid LCA were significantly decreased in arsenic-
exposed mice (Figure 3D), while DCA wasn’t changed. These results suggest that 1 ppm arsenic 
exposure also affects the bile acid homeostasis in mouse livers but its effects on livers are not 
identical with the effects in sera. 
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Figure 3. Arsenic exposure increased the level of some primary bile acids but decreased LCA in mouse 
livers. (Unpaired t test, N.S.: no significant difference; *p<0.05; n=6-8; Error bars show the SEM) 
3. Arsenic exposure perturbed the normal gut microbiota which is correlated with the 
changes of serum bile acids. 
Gut bacteria play a critical role in bile acid balance, thus we next investigated the arsenic-
induced changes in gut bacterial composition. We found that arsenic-exposed gut microbiota had 
a decreased alpha diversity (Figure 4A) and a different bacterial composition (Figure 4B). 
Specifically, the two major components of gut bacteria, Bacteroidetes and Firmicutes, were 
differentially changed by arsenic exposure, that the relative abundance of Bacteroidetes was 
significantly increased but Firmicutes was decreased in treated mice (Figure 4B).  
We then calculated the correlation between bacterial abundance and bile acid concentration. 
Hepatic bile acids couldn’t well be correlated with bacterial abundance. However, we found the 
level of multiple serum bile acids were highly correlated with the relative abundance of 
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Firmicutes and Bacteroidetes (Figure 4C). Taurine-conjugated bile acids, including TMCA, 
TCA and TCDCA, were significantly and positively correlated with Bacteroidetes but negatively 
associated with Firmicutes (Figure 4C). However, the level of free bile acids and secondary bile 
acids was more correlated with Bacteroidetes (Figure 4C).  
 
Figure 4. Arsenic exposure perturbed gut bacteria composition which is associated with the serum bile 
acid concentration. (A). Arsenic exposure decreased the alpha diversity (Observed OTUs) of the gut 
microbiota community. (B). Arsenic exposure increased the differentially altered the relative abundance 
of Bacteroidetes and Firmicutes (Metastats, N.S.: no significant difference; *p<0.05; **p<0.01; n=15; 
Error bars show the SEM). (C). Serum bile acid concentration is associated with the abundance of 
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Discussion 
In this study, we found arsenic exposure perturbed the bile acid balance in the mouse sera, 
that the most abundant primary bile acid species were decreased (Figure 1A), including MCA, 
CA and CDCA. Secondary bile acid LCA and DCA were also significantly decreased in arsenic-
exposed mice (Figure 1B). As a group of abundant metabolites, bile acids are not only as the 
tools to absorb dietary nutrition but also function as important signaling molecules regulating 
various physiological processes. There are many bile acid receptors widely expressing in diverse 
organs, including FXR, pregnane X receptor (PXR), vitamin D3 receptor (VDR), constitutive 
androstane receptor (CAR), and TGR5 (25). These receptors can be activated or inhibited by 
different bile acid species to regulate downstream gene expression. For example, several bile 
acid species, including CDCA, LCA, DCA and CA, are the agonists of transcription factor FXR 
(26), while TMCA is the major antagonist of FXR (27). FXR is mainly expressed in livers and 
intestines and is a master regulator determining the bile acid homeostasis, that it regulates the 
expression of a series of genes involving in bile acid synthesis, absorption and efflux (28). 
Additionally, LCA and DCA, which are derived from gut microbes, can activate TGR5 signaling 
which plays a critical role in glucose metabolism and homeostasis (29). Therefore, the arsenic-
caused decrease of those signaling bile acid species might affect the activation of their 
downstream pathways, which could be a part of the arsenic toxic effects.  
Gut microbiota is one of the key factors that regulate bile acid homeostasis. After being 
synthesized in livers, primary bile acids will be conjugated with taurine and will be exported to 
intestines to absorb dietary nutrition. Bile acids also have antimicrobial effects that they can 
inhibit the growth of gut microbes (30), but gut bacteria also can metabolize primary bile acids 
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and deeply change the form of bile acids (18). Taurine de-conjugation is one of the major 
reaction of bacteria-conducted bile acid metabolism that gut bacteria can cleave the taurine group 
from conjugated primary bile acids to produce unconjugated species. This reaction is mainly 
catalyzed by Bile Salt Hydrolase (BSH). In this study, we found arsenic exposure specifically 
decreased the unconjugated bile acid species in mouse sera (Figure 1A). Although the level of 
taurine-conjugated bile acids was no significant difference among controls and arsenic-treated 
groups, the ratios of unconjugated and taurine-conjugated bile acids were significantly decreased 
by arsenic treatment (Figure 2), including MCA/TMCA, CA/TCA, and CDCA/TCDCA. As 
demonstrated by our previous studies, arsenic exposure can profoundly change the normal 
composition of gut microbiota (10). Here, we found that the alpha-diversity of the bacterial 
community is significantly decreased in arsenic-treated mice (Figure 4A). Arsenic exposure also 
changed the relative abundance of the dominant bacterial phyla, including Bacteroidetes and 
Firmicutes (Figure 4B). Different bacterial components have different bile acid metabolism 
capabilities, and thus the arsenic-induced changes in gut bacteria might decrease their bile acid 
de-conjugation ability, which caused the decline of unconjugated/conjugated bile acid ratios in 
mouse sera. We did observe several bile acid species were highly correlated with the abundance 
of Bacteroidetes and Firmicutes (Figure 4C).   
Another important role of gut bacteria in bile acid metabolism is utilizing primary bile acids 
to produce secondary bile acids, such as LCA, DCA, MCA and UDCA (mouse). 
Corresponding to the perturbed gut bacteria, in this study, we also observed that secondary bile 
acids were significantly decreased in arsenic-treated mice, including LCA and DCA in sera and 
LCA in livers (Figure 1B and 3B). Since secondary bile acids are exclusively synthesized from 
gut microbiota, these results indicate that arsenic-caused changes in gut bacteria did affect the 
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bile acid profiles in host bodies. Various components in Firmicutes have been found to 
synthesize DCA and LCA by metabolizing CA and CDCA, such as Clostridium scindens and 
Lactobacillus plantarum (31, 32). Here, we did find Firmicutes was significantly decreased in 
arsenic-treated mice. Synthesizing secondary bile acids by gut bacteria not only changes the 
overall bile acid profiles but also provides some unique metabolic signals to host bodies, that 
both DCA and LCA have been found with many physiological effects. For example, both LCA 
and DCA are agonists of FXR and TGR5, which play important roles in bile acid, lipid, and 
glucose homeostasis (33). LCA and its derivatives, such as 3-keto-LCA, act as selective 
modulators of VDR (34). Moreover, secondary bile acids can also benefit to host by inhibiting 
pathogen infection (35). However, many studies also demonstrated that secondary bile acids are 
cytotoxic compounds and are correlated with the development of multiple diseases. For example, 
increased DCA levels are widely found in feces and sera of patients with colon cancer and some 
cholesterol gallstone disease (36). DCA also can promote the development of obesity-associated 
hepatocellular carcinoma (37). Taken together, our results indicate that arsenic exposure did 
change the gut microbiota and influence the secondary bile acid level in mouse bodies, but the 
specific health effects are still needed to be explored in the future. 
Interestingly, we found arsenic effects on mouse bile acid profiles were different in sera and 
livers. In mouse livers, arsenic exposure consistently increased the level of major primary bile 
acid species, whatever it is in free form or taurine conjugated form (Figure 3A). Bile acids are 
originally synthesized in livers and exported bile acids can back to livers by enterohepatic 
circulation. Therefore, the hepatic bile acids include both new synthesized and recirculated 
molecules, which may be the reason causing the difference between livers and sera. Bile acid 
synthesis in livers is controlled by a feedback regulatory mechanism. The FXR signaling both in 
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livers and in distal ilea plays a central role in controlling bile acid production, that activated FXR 
will downregulate the expression of key bile acid synthetic genes to reduce the bile acid pool (38, 
39). Previous studies demonstrated that gut microbiota performed bile acid metabolism could 
profoundly change the abundance of FXR ligands and thus influence the FXR activating level in 
livers and distal ilea (27). In 1 ppm arsenic-treated mice, we found typical FXR agonists were 
significantly decreased in sera, such as CDCA, LCA, DCA and CA, that LCA was also 
decreased in livers. This might indicate that arsenic treatment decreased the FXR activation level 
in livers and thus increased the bile acids synthesis, which thus can explain the consistent 
increase of hepatic bile acids. However, differential bile acid transportation also could cause 
different bile acid profiles in sera and livers. The specific mechanism of this phenomenon as well 
as the arsenic effects on bile acid synthesis and transportation still needs to be further addressed 
in the future study. 
In conclusion, this study demonstrated that arsenic exposure changed bile acid homeostasis 
in mice which are associated with the perturbed gut microbiota. Bile acids are important 
functional metabolites and signaling molecules, thus inducing bile acid dysfunction could be one 
of the underlying mechanisms of arsenic toxic effects on host bodies. Our study also highlights 
the important effects of arsenic-gut microbiota interactions on host health. Future studies are 
needed to elucidate which specific gut microbial components are changed by arsenic exposure to 
perturb the bile acid homeostasis and whether arsenic-induced bile acid changes influence the 
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